CD4 and neoplasm: The vaccine successfully triggered and sustained CD4+ T cell help-enhanced immune responses in the intestinal tract, and then in systemic circulation and the spleen, thus allowing WT1-specific T cells to reach the tumor where they exerted obvious antitumor activity.